Chymase inhibitors represent a potential therapeutic strategy for diseases driven by angiotensin II, TGF-β, and MMP-9, such as AAAs and cardiomyopathy, with a favorable anticipated safety profile in resting tissues.
May support chymase inhibitor development for AAA and cardiomyopathy; leaves open clinical translation pending human trials.
INTRODUCTION: Chymase converts angiotensin I to angiotensin II and it can also convert precursors of TGF-β and MMP-9 to their active forms. Therefore, diseases related to angiotensin II TGF-β, and MMP-9 could potentially be treated with chymase inhibitors. AREAS COVERED: This review discusses the appropriate targets and safety of chymase inhibitors. Six diseases with notable mortality or morbidity as targets of chymase inhibitors are focused on; abdominal aortic aneurysms (AAAs), nephropathy and retinopathy, cardiomyopathy, nonalcoholic steatohepatitis (NASH), organ fibrosis and intestinal diseases. EXPERT OPINION: If chymase inhibition proves to be a useful strategy for the attenuation of angiotensin II, TGF-β and MMP-9 in vivo, the application of chymase inhibitors is likely to become widespread in various diseases in the clinical setting. Chymase inhibitors are anticipated not to interfere with the homeostasis of resting tissues, that is, those not affected by injury or inflammation.
No takes yet. Share an insight, caveat, or question.
Takai et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: